CFO Ryan F. Robinson Disposes Shares and Stock Options in Tourmaline Bio Merger

Ryan F. Robinson, CFO of Tourmaline Bio, Inc., disposed of 14,366 shares of common stock and several employee stock options as part of the company's merger with Novartis AG. The merger, completed on October 28, 2025, involved a cash tender offer of $48.00 per share. The stock options, which were canceled and terminated, included 25,845, 16,000, 76,400, and 58,000 options with exercise prices ranging from $9.46 to $17.00. The transactions were executed in accordance with the merger agreement, and Robinson no longer holds any shares or options post-transaction.